A) Phase 1: To determine the maximal tolerated dose (MTD) of lenalidomide that can be safely
added to high-dose melphalan prior to autologous stem cell transplantation (ASCT).
B) Phase 2: To determine whether the addition of high-dose lenalidomide to ASCT followed by
maintenance standard-dose lenalidomide improves the response rate and duration of response
for relapsed multiple myeloma (RMM).